QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

QDEL

21.33

-3.27%↓

NERV

4.06

+7.12%↑

LSTA.US

2.12

+6.53%↑

Inicio・Lista de Acciones・Pharming Group NV

P
Pharming Group NV

Cerrado

1.453 -2.02

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.41

Máximo

1.483

Métricas clave
By Trading Economics
Ingresos	2.9M 7.5M
Ventas	4.1M 97M
BPA	0.006
Margen de beneficio	7.758
Empleados	404

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	379M 997M
Apertura anterior	3.47
Cierre anterior	1.453

Pharming Group NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 nov 2025, 21:34 UTC

Ganancias

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov 2025, 23:42 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov 2025, 23:24 UTC

Ganancias

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov 2025, 23:24 UTC

Ganancias

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov 2025, 23:23 UTC

Ganancias

JBS NV 3Q EPS 52c >JBS

13 nov 2025, 23:23 UTC

Ganancias

JBS NV 3Q Sales $22.6B >JBS

13 nov 2025, 23:04 UTC

Charlas de Mercado

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov 2025, 22:02 UTC

Ganancias

Nu Holdings 3Q Net $783M >NU

13 nov 2025, 22:01 UTC

Ganancias

Nu Holdings 3Q Rev $4.2B >NU

13 nov 2025, 21:51 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov 2025, 21:50 UTC

Ganancias

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov 2025, 21:41 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov 2025, 21:33 UTC

Charlas de Mercado

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov 2025, 21:33 UTC

Ganancias

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov 2025, 21:31 UTC

Ganancias

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov 2025, 21:25 UTC

Ganancias

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov 2025, 21:25 UTC

Ganancias

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov 2025, 21:23 UTC

Ganancias

Intchains Group 3Q Rev $1.3M >ICG

13 nov 2025, 21:03 UTC

Ganancias

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov 2025, 21:02 UTC

Ganancias

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov 2025, 21:01 UTC

Ganancias

Applied Materials 4Q Rev $6.8B >AMAT

13 nov 2025, 21:01 UTC

Ganancias

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparación entre iguales

Cambio de precio

Pharming Group NV Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Pharming Group NV Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.